New drug combo shows promise for Hard-to-Treat breast cancer

NCT ID NCT05586841

Completed Disease control Sponsor: Beijing 302 Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested two oral drugs, dalpiciclib and chidamide, in 22 people with HR+/HER2- advanced breast cancer whose disease had worsened after CDK4/6 inhibitor therapy. The main goal was to find the safest dose. Researchers also looked at how well the combination shrank tumors and what side effects occurred.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dalpiciclib and chidamide (oral drugs)
What this could lead to: If successful, this could provide a new treatment option for people with advanced breast cancer whose current therapy has stopped working.
What could go wrong: This is a very early, small phase 1b study with only 22 participants, so results may not apply broadly. The main goal is to find a safe dose, not yet to prove effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+, HER2-, ADVANCED BREAST CANCER

Contacts and locations

Locations

The Fifth Medical Center of PLA General Hospital

Beijing, Beijing Municipality, 100071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.